Sandesh Mahatme - 05 Dec 2025 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Reporting relationship: CFO
Issuer ticker: VOR
Reported as of: 05 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Dec 2025, 08:00:10 UTC
Prior SEC filing: 10 Jul 2025
Next SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: Adi Osovsky, Attorney-in-Fact

Key filing fact

Sandesh Mahatme filed Form 4 for Vor Biopharma Inc. (VOR) on 09 Dec 2025.

Key facts

This page summarizes Sandesh Mahatme's Form 4 filing for Vor Biopharma Inc. (VOR).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Dec 2025, 08:00.

Change

Previous filing in this sequence was filed on 10 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001511034 Primary reporting owner

Mahatme Sandesh

Relationship: CFO
Address: C/O VOR BIOPHARMA INC., 500 BOYLSTON STREET, SUITE 1350, BOSTON
Signature: Adi Osovsky, Attorney-in-Fact
Signature date: 09 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VOR transaction

Common Stock

Disposed to Issuer

Transaction value: $0
Shares: -694,137
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 05 Dec 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VOR transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +1,388,274
Change %
Price: $0.000000
Shares after: 1,388,274
Date: 05 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,388,274
Exercise price: $17.80
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The share counts herein reflect the reverse stock split.

Footnote F2

On December 5, 2025, the Issuer's Compensation Committee of the Board of Directors approved the cancellation of the previously awarded grant of 694,137 restricted stock units, which was reported in a Form 4 filed on July 10, 2025.

Footnote F3

The exercise price per share of common stock subject to the option will be (a) $17.80 per share, or (b) to the extent the option is exercised following the end of the Retention Period, $8.18 per share, the closing price of a share of common stock on the grant date (December 5, 2025). The "Retention Period" begins on December 5, 2025 and ends on the earlier of (i) December 5, 2027 or (ii) a Change in Control (as defined in the 2021 Plan) during the Reporting Person's Continuous Service (as defined in the 2021 Plan) with the Issuer. In the event that the Reporting Person's Continuous Service terminates for any reason or no reason prior to the end of the Retention Period, the exercise price per share of Common Stock subject to the Option will be as set forth in clause (a) above.

Footnote F4

1/4th of the shares underlying the option vest on July 1, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.